In the present study, we selected TMPRSS2:ERG fusion as it represents the most common genomic alteration in prostate cancer, 11 chromosomal deletions because deletions are the next most prevalent genomic alterations in prostate cancer and tumor cell proliferation. This evidence concerns the gene TMPRSS2 and prostate carcinoma.